combination therapy

1:33
Developing mantle cell lymphoma treatment for further success
John Kuruvilla
2:02
Update on selinexor for myeloma and large cell lymphomas
John Kuruvilla
0:51
MRD in the immuno-chemo era
Florence Cymbalista
2:53
MURANO: outcomes after the end of treatment
John Seymour
3:10
CLL treatment: statistical analysis in predictive medicine
Kevin Coombes
2:41
Comparing CLL regimens with MRD
John Seymour
3:48
Predicting suboptimal response through intermediate MRD
Andrew Rawstron
1:44
Novel combination therapies in CLL
Matthew Davids
2:32
Will cellular therapy have a role in CLL in 2020?
Anna Schuh
1:29
Venetoclax phase III trial disappointment
Lawrence Boise
1:22
Jarrod Longcor: ESMO highlights
Jarrod Longcor
1:00
Proof of principle to progress treatments
Jonathan Keats
1:22
Myeloma tackling combinations
Enrique Ocio
11:43
Will knowledge of the molecular pathology of lymphoma improve clinical trials?
David Maloney et al.
3:57
Bringing Dara into the first-line for multiple myeloma
Michael O’Dwyer
11:19
Immunotherapy for AML & ALL
Ivana Gojo et al.
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals